Review of ginsenoside CK shows potential antiplatelet, anti-inflammatory, and cardioprotective effects in cardiovascular disease models.

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published April 22, 2026 Medically reviewed April 25, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider ginsenoside CK as a potential agent with demonstrated antiplatelet and cardioprotective properties in preclinical models.

This review examined the potential of ginsenoside CK and protopanaxadiol type ginsenosides for conditions including cardiovascular disease, stroke, coronary artery disease, myocardial infarction, arrhythmias, heart failure, hypertension, ischemic stroke, and hemorrhagic stroke. The study population and specific sample size were not reported, as the evidence derives from various models rather than a single clinical trial.

The analysis demonstrated multiple biological activities, including antiplatelet and antithrombotic activities, inhibition of vascular smooth muscle cell proliferation, inhibition of endothelial inflammation, antiarrhythmic potential, anti-inflammatory properties, antioxidative properties, and mitochondrial protective properties. Efficacy was also demonstrated in models of myocardial ischemia/reperfusion and cerebral ischemia.

Safety and tolerability were assessed as showing low toxicity and good tolerability and safety without significant antagonism to other drugs. Adverse events, serious adverse events, and discontinuations were not reported in the source data. The review did not provide absolute numbers, p-values, or confidence intervals for these outcomes.

Key limitations include the observational nature of the review and the lack of reported sample sizes or specific follow-up durations. The practice relevance is currently uncertain due to the absence of clinical trial data. Clinicians should interpret these findings as preliminary mechanistic insights rather than established clinical efficacy.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedApr 2026

View Original Abstract ↓

Cardiovascular disease (CVD), comprising coronary artery disease, myocardial infarction, arrhythmias, heart failure, and hypertension, predominantly originates from dysfunction or obstruction within the cardiac and vascular systems. It has persistently remained the leading cause of death worldwide. The classification of stroke is based on its pathogenesis, with ischemic and hemorrhagic types representing distinct classifications. The etiology of stroke is attributed to cerebral vascular occlusion or rupture. It is frequently associated with hypoxic injury and neuronal necrosis, which poses a significant burden on individuals and public health systems. Ginsenoside compound K (CK), a secondary metabolite derived from the intestinal microbial transformation of protopanaxadiol type ginsenosides (e.g., Rb1, Rb2), exhibits high oral bioavailability and the capacity to cross the blood-brain barrier. Recent research has demonstrated that CK possesses antiplatelet and antithrombotic activities, inhibits vascular smooth muscle cell proliferation and endothelial inflammation, and shows low toxicity along with antiarrhythmic potential in the cardiovascular system. Furthermore, CK demonstrates significant anti-inflammatory, antioxidative, and mitochondrial protective properties, exhibiting efficacy in models of myocardial ischemia/reperfusion and cerebral ischemia. It exhibits good tolerability and safety without significant antagonism to other drugs and is increasingly recognized as a promising multi-target natural therapeutic candidate. The objective of this review is twofold: first, to synthesize recent findings on the mechanisms by which ginsenoside CK confers protection in cardiovascular and cerebrovascular conditions; and second, to assess its translational potential and highlight its prospective role in next-generation cardiovascular therapies.